MARATTO

article · QJM

Effect of Ascorbic Acid Alone versus Combined Ascorbic Acid with Iron Supplement in Management of Functional Iron Deficiency Anemia in Hemodialysis Patients

Abstract

Abstract Background Anemia is a prevalent symptom of ESKD and is associated with an increased risk of hospitalization and mortality. Anemia is defined as a lack of erythropoietin production, decreased red blood cell survival, and blood loss from the dialysis circuit. Aim of the Work The goal of this study is to determine the efficacy of oral ascorbic acid (AA) in treating anemia in persons with ESKD who also have elevated ferritin levels. Patients and Methods 50 patients with early-stage kidney disease (ESKD) who underwent standard HD were divided into two groups: group A (25 patients) received oral ascorbic acid 250 mg once daily for six months along with iron supplementation, while group B (25 patients of the same age and sex) received oral ascorbic acid without iron supplementation. Results Group A (combined vitamin C and iron) exhibited considerably increased transferrin saturation after 3 and 6 months of treatment. At 3 and 6 months following treatment, transferrin saturation increased in individuals in Group A (combined vitamin C and iron) compared to baseline. Conclusion The current study's findings suggest that anemia is a common concern among ESRD patients, particularly those on hemodialysis. Iron and vitamin C can be used together to treat iron deficient anemia more effectively.

Research topics

  • Iron Metabolism and Disorders
  • Dialysis and Renal Disease Management

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1093/qjmed/hcae175.413

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.